Fetoplacental endothelial dysfunction in gestational diabetes mellitus and maternal obesity: A potential threat for programming cardiovascular disease

Biochim Biophys Acta Mol Basis Dis. 2023 Dec;1869(8):166834. doi: 10.1016/j.bbadis.2023.166834. Epub 2023 Aug 2.

Abstract

Gestational diabetes mellitus (GDM) and maternal obesity (MO) increase the risk of adverse fetal outcomes, and the incidence of cardiovascular disease later in life. Extensive research has been conducted to elucidate the underlying mechanisms by which GDM and MO program the offspring to disease. This review focuses on the role of fetoplacental endothelial dysfunction in programming the offspring for cardiovascular disease in GDM and MO pregnancies. We discuss how pre-existing maternal health conditions can lead to vascular dysfunction in the fetoplacental unit and the fetus. We also examine the role of fetoplacental endothelial dysfunction in impairing fetal cardiovascular system development and the involvement of nitric oxide and hydrogen sulfide in mediating fetoplacental vascular dysfunction. Furthermore, we suggest that the L-Arginine-Nitric Oxide and the Adenosine-L-Arginine-Nitric Oxide (ALANO) signaling pathways are pertinent targets for research. Despite significant progress in this area, there are still knowledge gaps that need to be addressed in future research.

Keywords: Adenosine receptors; Cardiac function; Endothelial dysfunction; Fetal development; Gestational diabesity; Metabolic syndrome; Nitric oxide.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arginine / metabolism
  • Cardiovascular Diseases* / metabolism
  • Diabetes, Gestational* / metabolism
  • Female
  • Humans
  • Nitric Oxide / metabolism
  • Obesity, Maternal* / complications
  • Obesity, Maternal* / metabolism
  • Placenta / metabolism
  • Pregnancy

Substances

  • Nitric Oxide
  • Arginine